Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)

S.A. to Present Data on its Allogeneic CAR T Cell Programs at American

Society of Gene & Cell Therapy Annual Meeting

NEW YORK--(BUSINESS WIRE)--May 7, 2015--Regulatory News:

Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS - Nasdaq Global Market:

CLLS), a pioneering gene-editing company employing proprietary

technologies to develop best-in-class products in the emerging field of

immuno-oncology, today announced that pre-clinical data on its

engineered allogeneic CAR T-cells will be featured in an oral

presentation at the American Society of Gene & Cell Therapy (ASGCT) 18th

Annual Meeting. The meeting will be held from May 13 to 16, 2015 in New

The company will also have three posters that will present how its gene

editing technologies, including TALEN , could enable the efficient

manufacture of "off-the-shelf" CAR T-cells.

The selected presentations include:

UCART19, an Allogeneic "Off-the-Shelf" Adoptive T-Cell

Immunotherapy Against CD19+ B-Cell Leukemias

- Session title: Cancer - Immunotherapy, Cancer Vaccines II

Time: Saturday, May 16, 2015, 10:30 am to 10:45 am

Targeted Genome Modifications for Improved Adoptive Immunotherapy

Session: Gene Targeting and Gene Correction II

Thursday, May 14, 2015, 5:30 pm to 7:00 pm

A Multidrug Resistant Engineered CAR T-Cell for Allogeneic

Combination Immunotherapy

Poster Session: Cancer -

Immunotherapy, Cancer Vaccines II

Presentation Time: Thursday, May

14, 2015 - 5:30 pm to 7:00 pm

Allogeneic CAR T-Cells Targeting CD123 for Adoptive Immunotherapy

of Acute Myeloid Leukemia (AML)

Poster Session: Cancer -

Immunotherapy, Cancer Vaccines II

Presentation Time: Thursday, May

14, 2015 - 5:30 pm to 7:00 pm

Posters will be posted on Cellectis' website on May 13, 2015.

Cellectis is a gene-editing company focused on developing

immunotherapies based on gene edited engineered CAR T-cells (UCART). The

company's mission is to develop a new generation of cancer therapies

based on engineered T-cells. Cellectis capitalizes on its 15 years of

expertise in genome engineering - based on its flagship TALEN products

and meganucleases and pioneering electroporation PulseAgile technology -

to create a new generation of immunotherapies. CAR technologies are

designed to target surface antigens expressed on cells. Using its

life-science-focused, pioneering genome-engineering technologies,

Cellectis' goal is to create innovative products in multiple fields and

with various target markets. Cellectis S.A. is listed on the Nasdaq

Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker:

ALCLS). To find out more about us, visit our website: www.cellectis.com

Jennifer Moore, 917-580-1088

Brad Miles, 646-513-3125

Harnest, 646-385-9008

VP Finance and Investor Relations